.jpg)
SARS-CoV-2 peptides and proteins with reduced adherence to Angiotensin Converting Enzyme-2
EP21382574.8
The present invention refers to a mutated amino acid sequence, a mutated receptor-binding domain and a mutated Spike protein of SARS-CoV-2 with reduced adherence to Angiotensin Converting Enzyme-2 (ACE-2), antibodies that specifically binds to them, pharmaceutical and/or veterinary compositions comprising them, nucleic acids that encode them and therapeutic and prophylactic uses. In particular, the present invention refers to their uses in the prophylaxis and/or treatment of a SARS-CoV-2 infection and COVID disease.
La variante del Spike de SARS-CoV-2 desarrollada preserva la mayor parte del sitio de unión a ACE-2, multiplica la concentración del inmunógeno en los nódulos linfáticos, aumenta el título de anticuerpos neutralizantes y reduce el potencial riesgo asociado al bloqueo de receptores ACE-2 debido a la propia vacunación. Mejora de la vacunación frente a SARS-CoV-2 y enfermedad COVID.